Analysts: Alexion Offers a Buying Opportunity and 4 New Opinions Investors Must Read

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR): The company’s price target has been increased by Deutsche Bank after the firm met with management. The firm believes the Juxtapid U.S. launch is already ahead of expectations, and it keeps its Buy rating on the stock.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

AEGR